Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 4 Major Wholesalers’ Price Settlement Rates Lower than 2 Years Ago, Negotiations Charging into Final Phase: April-Dec. Earnings
February 7, 2013
- Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
- Sales and Profits Jump for Shionogi in April-December with US Sales Recovery
February 6, 2013
- Latuda Serves as Driving Force for Growth in North American Market: DSP President Tada
February 6, 2013
- Takeda Lowers Full-Year Sales Forecast for Nesina, but Says Nesina Remains “Fastest-Growing DPP-4 Inhibitor”
February 6, 2013
- Sales in Emerging Markets Contribute to Growth in Sales for April-December Despite Fall in Sales of All 4 Major Products: Takeda
February 6, 2013
- Daiichi Sankyo Starts PIII Trial of ARQ 197 in HCC Patients
February 5, 2013
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
- Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
- Teijin Pharma Appoints Hiroshi Uno as New President Effective from April 1
February 5, 2013
- 13.9 Bil. in Royalties from Gilenya Help Boost Consolidated Sales for April-December: MTPC
February 5, 2013
- Kyowa Kirin Posts Record Operating Profit for 2012; Sales Up 9% in Pharma Division
February 5, 2013
- Eisai’s Operating Profit Drops 34% in April-December as Aricept Sales Fall
February 4, 2013
- Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
- Astellas April-Dec. Earnings: XTANDI Starts Off on Good Note, Could Outstrip Full-Year Target
February 4, 2013
- Kyowa Kirin to Launch 3 In-House Products in Europe and US, Aims for Sales of 358 Billion Yen in 2015: New Midterm Plan
February 4, 2013
- Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
- Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
- Chugai Begins Development of Hyperlipidemia Antibody RG7652
February 1, 2013
- Oncology Products Boost Sales, Profits in 2012, but Both Fall Short of Midterm Targets: Chugai
February 1, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…